Clinical data showed that anti-TIGIT antibody tiragolumab plus anti–PD-L1 antibody atezolizumab improved overall response and PFS and was well tolerated compared with anti–PD-L1 monotherapy in patients with PD-L1–positive metastatic NSCLC (93, 94). This evidence concerns the gene CD274 and non-small cell lung carcinoma.